ClinicalTrials.gg
CompletedNCT01955564Updated Jun 20, 2017Results posted

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

A Phase 1 interventional study of NW-3509a in Schizophrenia, sponsored by Newron Pharmaceuticals SPA. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by Newron Pharmaceuticals SPA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
754th of 1,319
54 · median 66
Started
2013
with 67 others
Phase 1
196 of 1,465
10 open now
Registered
773rd of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 754th largest by enrollment of the 1,319 interventional ones that give a count, is one of 68 that started in 2013, is one of 196 in phase 1, and was the 773rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, 8-day, randomized, double-blind, placebo-controlled, sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single escalating oral doses of NW-3509A in healthy male volunteers. Six independent cohorts of 12 volunteers each will participate in this study, with the first 9 volunteers in each cohort to qualify being randomized to receive study medication and the remaining 3 to be used as backups/ alternates. In each cohort, 6 subjects will be randomly assigned to receive NW-3509A and 3 subjects will receive placebo.

Read the detailed description

Doses from 1 to 30 mg were tested

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demographics

Volunteers will meet the following demographic inclusion criteria:

  1. Age - between 18 and 45 years of age, inclusive.
  2. Sex - males.
  3. The subject has a body weight of at least 45 kg and a of ≤30.

    Procedural

    Volunteers will meet the following procedural criteria:

  4. They are cooperative, able to take oral medication, willing to complete all aspects of the study, and capable of doing so.
  5. They will be able to understand the instructions and fully participate.
  6. They will have provided written prior to participating in the study.
  7. The subject is in good health with no history of significant medical disease as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment:

General Medical Status

  1. An advanced, severe, or unstable disease of any type that may interfere with any of the study evaluations, including any medical condition that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical or mental status of the volunteer to a significant degree or put the volunteer at special risk (e.g., liver or kidney disease; );
  2. A disability that may prevent the volunteer from completing all study requirements (e.g., blindness, deafness, severe language difficulty);
  3. A current diagnosis of active, uncontrolled peptic ulceration within the last year;
  4. A current diagnosis of acute, severe, or unstable asthmatic condition.

    Cardiovascular

  5. A current diagnosis of severe or unstable cardiovascular disease;
  6. A current diagnosis of sick-sinus syndrome or conduction deficits (e.g., sino-atrial block (\<0.22), second or third degree atrio-ventricular block);
  7. Any history or current evidence of a cardiac illness as determined by the investigator;
  8. Any abnormality, including a disorder of rate, rhythm, or conduction, or other morphological changes, or a interval (Fridericia's correction formula) on the ECG >450 msec. The 12-lead ECG will be used for determining the suitability of the subject for inclusion in the study (determined by the investigator);
  9. Vital signs (supine) outside the following ranges:

    • Systolic blood pressure below 100 or above 139 mmHg;
    • Diastolic blood pressure below 50 or above 89 mmHg;
    • Radial pulse below 50 or above 90 bpm.

    CNS related

  10. Any history or current diagnosis of any neurodegenerative illness;
  11. History or current diagnosis of epilepsy or seizure disorder.

    Psychiatric

  12. Any past or current psychiatric illness ( Axis 1 diagnosis);
  13. Subjects with current or past suicidal ideation.

    Study-specific criteria

  14. History of serious adverse reactions or to any drug;
  15. Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis);
  16. Alcohol or drug abuser; currently or at any time in the last 5 years;
  17. Abnormal physical findings of clinical significance at the screening examination or baseline that would interfere with the objectives of the study;
  18. Need of any prescription medication within 14 days prior to the administration of the study drug, and/or non-prescription medication within 7 days prior to the administration of the drug;
  19. Participation in other clinical trials during the last 2 months in which an drug or a commercially available drug was tested;
  20. Loss of 500 ml or more of blood during the 3-month period before the study, e.g. as a donor.
  21. Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, inflammatory bowel disease, chronic symptoms of pronounced constipation or diarrhea, or conditions associated with total or partial obstruction of the urinary tract;
  22. Symptoms of a significant somatic or mental illness in the four-week period preceding study drug administration;
  23. History of and/or C, and/or positive serology results, which indicate the presence of hepatitis B and/or C (Hepatitis B surface antigen and/or antibody to );
  24. Positive results from the serology;
  25. Positive results of the drug and alcohol tests at screening and/or check-in at the unit;
  26. Smoker; currently or at any time in the last 5 years;

    Laboratory abnormalities

  27. Clinically significant abnormalities in routine laboratory examinations (hematology; blood chemistry, including electrolytes and liver and kidney function tests; urinalysis), as determined by the Principal Investigator in consultation with the Sponsor, at the screening evaluation;
  28. Clinically important laboratory abnormalities in thyroid function tests at screening:

    • TSH > 8.0 mU/L and/or Free T4 \< 9 pmol/L;

    Concomitant therapy

  29. A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to NW-3509A. Possible examples are volunteers who have experienced hypersensitivity reactions to sodium channel blockers;
  30. Ingested any of the following substances:

    • An investigational drug during the past 2 months;
    • A drug or treatment known to cause major organ system toxicity during the past year;
    • Any prescription drug or OTC product if taken continuously (Medical Monitor from Newron should be contacted if the Investigator wants to include a volunteer who is taking an OTC product);
    • Alcohol intake should be limited to 2 drinks per day during the 2 weeks prior to dosing; alcohol consumption will be prohibited from 72 hours prior to admittance on Day -1 through to the final safety evaluations on Day 8.
    • Caffeine-containing products should be limited (equivalent of 2 cups of coffee per day) during the 2 weeks prior to dosing and through to the final safety evaluations on Day 8.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Cohort 1

    NW-3509a - 1mg or placebo

    Drug: NW-3509a

  • Experimental
    Cohort 2

    NW-3509a 2mg or placebo

    Drug: NW-3509a

  • Experimental
    Cohort 3

    NW-3509a 5mg or placebo

    Drug: NW-3509a

  • Experimental
    Cohort 4

    NW-3509a 10 mg or placebo

    Drug: NW-3509a

  • Experimental
    Cohort 5

    NW-3509a 20 mg or placebo

    Drug: NW-3509a

  • Experimental
    Cohort 6

    NW-3509a 30 mg or placebo

    Drug: NW-3509a

Interventions

  • DrugNW-3509a

    single dose

    Also known as: NW-3509

06

What researchers measure

Primary outcomes

  1. Physical Examination Shift Table

    Physical examinations were carried out on the following: Lymph nodes, mouth, neck, nervous system, nose, skin and throat.

    Time frame: Day -1(pre-dose) through Day 8 (Discharge)

Secondary outcomes

  1. Maximum Plasma Concentration of NW-3509A at Doses Tested

    Plasma concentration data, derived PK parameters, and urine data are summarized as maximum plasma concentration (Cmax). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).

    Time frame: Baseline up to 32 hours post-dose

  2. Total Drug Exposure Over Time (AUC0-t) of NW-3509A at Doses Tested

    Plasma concentration data, derived PK parameters, and urine data were summarized as total drug exposure over time (AUC0-t). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).

    Time frame: Baseline up to 32 hours post-dose

07

Results

Posted Jun 20, 2017

Participant flow

A total of 54 healthy males, who were between the age of 18-45 years old, with a minimum body weight of 45 kg and body mass index of more than or equal to 30, were recruited and observed in the period from 23rd of July 2013 till 19th of September 2014 in this study conducted at a single site in the US.

Participant flow — Overall Study
MilestonePlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Started18666666
Completed18666666
Not completed0000000

Outcome measures

PrimaryPhysical Examination Shift Table

Physical examinations were carried out on the following: Lymph nodes, mouth, neck, nervous system, nose, skin and throat.

Time frame:
Day -1(pre-dose) through Day 8 (Discharge)
Reported as:
Number · Participants abnormal at end of study
Physical Examination Shift Table
Participants abnormal at end of studyPlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Physical Examination Shift Table1100110
SecondaryMaximum Plasma Concentration of NW-3509A at Doses Tested

Plasma concentration data, derived PK parameters, and urine data are summarized as maximum plasma concentration (Cmax). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).

Time frame:
Baseline up to 32 hours post-dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration of NW-3509A at Doses Tested
ng/mLCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Maximum Plasma Concentration of NW-3509A at Doses Tested2.08 ± 1.203.49 ± 1.9814.2 ± 7.222.5 ± 16.436.4 ± 30.193.3 ± 18.0
SecondaryTotal Drug Exposure Over Time (AUC0-t) of NW-3509A at Doses Tested

Plasma concentration data, derived PK parameters, and urine data were summarized as total drug exposure over time (AUC0-t). The plasma concentrations of NW-3509A in the samples taken from the subjects receiving placebo were below the limit of quantification (\<1.00 ng/mL) in all cases (n=18).

Time frame:
Baseline up to 32 hours post-dose
Reported as:
Mean · ng.h/mL
Total Drug Exposure Over Time (AUC0-t) of NW-3509A at Doses Tested
ng.h/mLCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Total Drug Exposure Over Time (AUC0-t) of NW-3509A at Doses Tested6.71 ± 9.2413.4 ± 11.256.7 ± 30.5101 ± 86166 ± 175350 ± 34

Adverse events

Collected over Adverse Event evaluations were performed during the screening period, at baseline, Day 2 and Day 8. In addition, all subjects were followed up for 30 days after their dose of study medication for the occurrence of any SAEs. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/18 (0%)6/18 (33.3%)
Cohort 1—0/6 (0%)3/6 (50%)
Cohort 2—0/6 (0%)1/6 (16.7%)
Cohort 3—0/6 (0%)3/6 (50%)
Cohort 4—0/6 (0%)2/6 (33.3%)
Cohort 5—0/6 (0%)5/6 (83.3%)
Cohort 6—0/6 (0%)3/6 (50%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Postural Orthostatic and tachycardia syndromeCardiac disorders0/180/60/60/60/60/62/6
ConfusionInjury, poisoning and procedural complications1/180/60/60/60/62/60/6
ConstipationGastrointestinal disorders1/180/60/61/60/60/60/6
NauseaGastrointestinal disorders0/180/60/61/60/60/60/6
Feeling hotGeneral disorders0/180/60/60/60/60/61/6
Dermatitis contactSkin and subcutaneous tissue disorders0/181/60/60/60/61/60/6
ExcoriationSkin and subcutaneous tissue disorders0/180/60/60/61/60/60/6
Thermal burnSkin and subcutaneous tissue disorders0/180/60/60/61/60/60/6
Blood creatine phosphate kinaseInvestigations0/180/60/60/60/61/60/6
ArthralgiaMusculoskeletal and connective tissue disorders0/180/60/61/60/60/60/6

Baseline characteristics

9 healthy volunteers were assigned per cohort, within which 6 subjects received NW-3509A and 3 subjects received placebo by randomised selection.

Age, Customized
Age, Customized(years)PlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
18-4531.27 ± 7.7128.33 ± 6.3123.83 ± 6.9130.33 ± 8.1234.83 ± 5.8529.50 ± 3.5124.33 ± 3.5628.92 ± 3.88
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Female00000000
Male1866666654
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Hispanic or Latino20112208
African American724434125
Asian12001015
Caucasian821100315
Native American00000011
Region of Enrollment
Region of Enrollment(participants)PlaceboCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
United States1866666654
08

Study locations

1 site
  • Collaborative Neuroscience Network-Clinical Pharmacology Unit
    Long Beach, California 90806, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Sep 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2013
First posted
Oct 7, 2013
Start
Jun 2013
Primary completionActual
Sep 2014
CompletionActual
Feb 2015
Results first posted
Jun 20, 2017
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01955564
Responsible party
Sponsor
First posted
Oct 7, 2013
Start date
Jun 2013
Primary completion
Sep 2014
Completion
Feb 2015
Results posted
Jun 20, 2017
Last update
Jun 20, 2017

Study contacts

Mark Leibowitz, MD
principal investigator · Collaborative Neuroscience Network Phase I Unit
Ravi Anand, MD
study director · Newron Pharmaceuticals SPA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion